首页> 美国卫生研究院文献>American Journal of Rhinology Allergy >Allergic rhinoconjunctivitis in the Australian population: Burden of disease and attitudes to intranasal corticosteroid treatment
【2h】

Allergic rhinoconjunctivitis in the Australian population: Burden of disease and attitudes to intranasal corticosteroid treatment

机译:澳大利亚人群过敏性鼻结膜炎:疾病负担和对鼻内糖皮质激素治疗的态度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:Allergic rhinoconjunctivitis (AR/C) is a global health problem causing significant morbidity and has a major impact on quality of life (QOL) and health expenditure. Despite the widespread prevalence, the overall health impact of AR/C may be underappreciated. The results of a survey designed to capture the burden of allergic rhinitis within the Asia-Pacific region have been published recently. Of particular note when evaluating treatment in this region was the fact that despite the value of intranasal corticosteroid (INCS) use, only a small percentage of patients used them. Whether this same trend is present within the population of Australian sufferers is unknown. This study examines the burden of AR/C and explores use of, and attitudes, to INCS sprays in the Australian population.
机译:背景:变应性鼻结膜炎(AR / C)是一个全球性的健康问题,引起严重的发病率,并且对生活质量(QOL)和健康支出产生重大影响。尽管普遍流行,AR / C的整体健康影响可能仍未得到充分认识。最近一项旨在捕获亚太地区过敏性鼻炎负担的调查结果已经发表。在评估该区域的治疗时,特别值得注意的是,尽管鼻内使用皮质类固醇(INCS)具有价值,但只有一小部分患者使用了它们。在澳大利亚患者中是否也存在同样的趋势尚不清楚。这项研究检查了AR / C的负担,并探讨了澳大利亚人口对INCS喷雾剂的使用和态度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号